Procter & Gamble (P&G) has signed a four-year agreement to use bioinformatics software to help boost the development of new products including pharmaceuticals, consumer goods and biofuels.
The firm will use Eagle Genomics’ secure, cloud-based, Eaglecore platform to organise existing data and integrate existing data with new analysis from across the company.
Dr Abel Ureta-Vidal, CEO of Eagle, said: “Eaglecore is an extremely powerful platform and will have a major impact on P&G’s approach to their current research projects.
“By using out platform, P&G will be able to better reference, manage and use all of their data to develop new insights and products, saving both time and development costs.”
The deal will see P&G take a four-year license for an undisclosed sum, which will include additional data curation services. The agreement follows a long partnership between the two companies involving Eagle’s consultancy arm, which has been used to support past research.
Eagle, which allows large-scale genomics data and data generation technologies to be applied to world issues, was earlier this year awarded funding from the UK’s Department of Health to develop proposals to help to with treating rare diseases and cancer.